| Sign In to gain access to subscriptions and/or personal tools. |
Long-term daclizumab therapy in relapsing-remitting multiple sclerosisNeurovirology Research Laboratory, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA, jrose{at}genetics.utah.edu
Monica A. Rojas Neurovirology Research Laboratory, VASLCHCS and Department of Neurology, University of Utah, Salt Lake City, UT, USA
Noel G. Carlson Neurovirology Research Laboratory, Geriatric Research Education Clinical Center (GRECC), VASLCHCS, Departments of Neurology, Neurobiology and Anatomy, Brain Institute and Center on Aging, University of Utah, Salt Lake City, UT, USA
Thomas L. Miller Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA We performed a retrospective review of side effects and clinical outcomes in relapsing-remitting (RR) multiple sclerosis (MS) patients receiving long-term treatment with daclizumab. Twelve patients with RR MS were initially treated with daclizumab at 1 mg/kg IV, again 14 days later and then monthly treatments (average duration 42.1 months). Daclizumab dose (0.85 mg/kg to 1.5 mg/kg) was adjusted based on clinical response. Daclizumab was generally well tolerated. There was a significant reduction in relapse rate and improvement in Expanded Disability Status Scores (EDSSs) (p < 0.0001). Long-term treatment with daclizumab in RR MS patients has apparent benefit that will require formal confirmation.
Key Words: long-term daclizumab therapy • interleukin 2 receptor alpha • side effects • clinical outcomes
This version was published on September
1, 2009 Therapeutic Advances in Neurological Disorders, Vol. 2, No. 5,
291-297 (2009) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
